B. Kaiser

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

A. Tolcher, Toshio Shimizu, K. Papadopoulos, 2012, Clinical Cancer Research.

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

A. Tolcher, K. Papadopoulos, D. Rasco, 2018 .

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study: The START Center experience.

A. Tolcher, K. Papadopoulos, M. Beeram, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

A. Tolcher, I. Puzanov, K. Papadopoulos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer

A. Tolcher, S. Gunn, B. Kaiser, 2013, Journal of Ovarian Research.

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

A. Tolcher, D. Gandara, Paul D. Smith, 2014, Clinical Cancer Research.

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

A. Tolcher, B. Kaiser, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.